Tracey McLaughlin, MD
Endocrinology, Diabetes & Metabolism · Stanford, CANPI 1407982663
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,091 of the $52,968 with a category attached, or 90.8%. 13 manufacturers reported payments, led by Eiger Biopharmaceuticals, Inc. at 45.9% of the total. Reporting peaked in 2023 at $24,478 and has fallen 68.2% since, to $7,790 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $814.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eiger Biopharmaceuticals, Inc.$24K
- Regeneron$23K
- AstraZeneca$2K
- Dexcom, Inc.$2K
- Gilead$2K
- Boehringer Ingelheim$303
- plus $773 from 7 others
Across 63 payments — averaging $26,469 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$846K
- Merck$320K
- Recordati_rare_diseases_inc.$265K
- Novo Nordisk$185K
- Eiger Biopharmaceuticals, Inc.$29K
- Genentech, Inc.$16K
- plus $6K from 1 others
What the payments were for
- Consulting fees$48,09191%
- Speaking & faculty fees$1,5503%
- Travel & lodging$9742%
- Food & beverage$2,2844%
- Other$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eiger Biopharmaceuticals, Inc. | 11 | $24,334 |
| Regeneron | 33 | $22,540 |
| AstraZeneca | 1 | $1,880 |
| Dexcom, Inc. | 3 | $1,639 |
| Gilead | 1 | $1,500 |
| Boehringer Ingelheim | 5 | $303 |
| Abbott | 3 | $300 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Corcept Therapeutics | 3 | $145 |
| Lilly USA, LLC | 1 | $72 |
| Novo Nordisk | 1 | $39 |
| Medicure Pharma Inc. | 1 | $15 |
| Insulet Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,880
- DEXCOM STELO GLUCOSE BIOSENSOR$550
- FREESTYLE LIBRE 3$230
- ZEGALOGUE$189
How this compares
$52,968 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gvoke Hypopen 2-PackGlucagon | 17 | $61,627 |
| MounjaroTirzepatide | 46 | $48,763 |
| TrulicityDulaglutide | 39 | $46,039 |
| OzempicSemaglutide | 43 | $39,551 |
| JardianceEmpagliflozin | 32 | $37,164 |
| JanuviaSitagliptin Phosphate | 36 | $33,361 |
| BaqsimiGlucagon | 21 | $17,760 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,849 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $4,409 |
| NovologInsulin Aspart | 14 | $4,172 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,897 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,830 |
| Glucagon Emergency KitGlucagon | 11 | $3,581 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 14 | $2,776 |
| Novolog FlexpenInsulin Aspart | 15 | $2,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $72 | $112,561106 claims |
| Novo NordiskOzempic, Novolog | $39 | $43,72357 claims |
| Boehringer IngelheimJardiance | $303 | $37,16432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Stanford
- Andrew HoffmanStanford$63K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.